Related Experiment Video
Updated: Jul 10, 2026

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
Oral antivirals for chronic hepatitis B
Albert D Min1, Jules L Dienstag
1Division of Digestive Diseases, Beth Israel Medical Center, First Avenue at 16th Street, New York, NY 10003, USA.
Abstract:
Four oral antiviral agents have been approved by the United States Food and Drug Administration (FDA) for the treatment of chronic hepatitis B: lamivudine, adefovir, entecavir, and telbivudine. This article reviews the durability of response, dose regimen, predictors of response, safety, and problems with resistance of these four agents and of promising agents currently in phase III clinical trials for the treatment of patients who have hepatitis B e antigen-positive and -negative chronic hepatitis B.
Related Concept Videos
Antiviral Nucleoside Inhibitors
Hepatitis
Viral Hepatitis I: Introduction
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Inhibitors Of Virion Release
